Abstract In 2011, the National Institute on Aging and Alzheimer's Association created
separate diagnostic recommendations for the preclinical, mild cognitive impairment, and …

Technologies for imaging the pathophysiology of Alzheimer disease (AD) now permit
studies of the relationships between the two major proteins deposited in this disease …

This article describes the public health impact of Alzheimer's disease (AD), including
incidence and prevalence, mortality and morbidity, costs of care, and the overall impact on …

Although dementia has been described in ancient texts over many centuries (eg,“Be kind to
your father, even if his mind fail him.”–Old Testament: Sirach 3: 12), our knowledge of its …

As the field begins to test the concept of a" preclinical" stage of neurodegenerative disease,
when the pathophysiological process has begun in the brain, but clinical symptoms are not …

The proliferation and activation of microglial cells is a hallmark of several neurodegenerative
conditions. This mechanism is regulated by the activation of the colony-stimulating factor 1 …

Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological
abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many …

Ten years ago we first proposed the Alzheimer's disease (AD) mitochondrial cascade
hypothesis. This hypothesis maintains that gene inheritance defines an individual's baseline …

Importance Typical cognitive aging may be defined as age-associated changes in cognitive
performance in individuals who remain free of dementia. Ideally, the full adult age spectrum …

Disease-modifying treatments for Alzheimer disease (AD) have focused mainly on reducing
levels of amyloid-β (Aβ) in the brain. Some compounds have achieved this goal, but none …